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A B S T R A C T
Purpose
Although anatomic segmentectomy has been considered a compromised procedure by many
surgeons, recent retrospective, single-institution series have demonstrated tumor recurrence and
patient survival rates that approximate those achieved by lobectomy. The primary objective of this
study was to use propensity score matching to compare outcomes after these anatomic resection
approaches for stage I non–small-cell lung cancer.
Patients and Methods
A retrospective data set including 392 segmentectomy patients and 800 lobectomy patients was used to
identify matched segmentectomy and lobectomy cohorts (n 312 patients per group) using a propensity
score matching algorithm that accounted for confounding effects of preoperative patient variables. Primary
outcome variables included freedom from recurrence and overall survival. Factors affecting survival were
assessed by Cox regression analysis and Kaplan-Meier estimates.
Results
Perioperative mortality was 1.2% in the segmentectomy group and 2.5% in the lobectomy group
(P  .38). At a mean follow-up of 5.4 years, comparing segmentectomy with lobectomy, no
differences were noted in locoregional (5.5% v 5.1%, respectively; P  1.00), distant (14.8% v
11.6%, respectively; P  .29), or overall recurrence rates (20.2% v 16.7%, respectively; P  .30).
Furthermore, when comparing segmentectomy with lobectomy, no significant differences were
noted in 5-year freedom from recurrence (70% v 71%, respectively; P  .467) or 5-year survival
(54% v 60%, respectively; P  .258). Segmentectomy was not found to be an independent
predictor of recurrence (hazard ratio, 1.11; 95% CI, 0.87 to 1.40) or overall survival (hazard ratio,
1.17; 95% CI, 0.89 to 1.52).
Conclusion
In this large propensity-matched comparison, lobectomy was associated with modestly increased
freedom from recurrence and overall survival, but the differences were not statistically significant.
These results will need further validation by prospective, randomized trials (eg, Cancer and
Leukemia Group B 140503 trial).
J Clin Oncol 32:2449-2455. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Although surgical resection of clinical stage I non–
small-cell lung cancer (NSCLC) remains the stan-
dard of care, controversy exists with regard to the
extent of parenchymal resection required for local
control of the tumor and disease-free survival.1-5
Intentional use of anatomic segmentectomy for the
treatment of small peripheral lung cancers was first
performed by Jensik et al.6 Lobectomy has been con-
sidered the standard of surgical care for early-stage
NSCLC identified in the physiologically fit patient7;
however, anatomic segmentectomy performed by
open surgical techniques or through video-assisted
thoracic surgical approaches has gained enthusiasm
by many surgical groups over the years.8-10
Additionally, nonsurgical approaches using hypo-
fractionated, stereotactic radiotherapy and image-
guided probing of the tumor for delivery of
radiofrequency or microwave energy to focally
ablate small peripheral lung cancers are also
challenging the concept of universal selection
of anatomic lobectomy for clinical stage
I NSCLC.11,12
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We focused our present analysis on clinical stage I NSCLC, be-
cause describing the results of various surgical resection approaches
related to pathologic stage I disease necessarily biases outcomes to-
ward surgical interventions with greater objective intraoperative stag-
ing of the pulmonary hilum and mediastinum. This is an important
point of distinction, in that it is appreciated that pathologic upstaging
from the pretreatment clinical stage may be seen in up to 30% of
patients, even with modern computed tomography (CT) and positron
emission tomography staging techniques being used.13,14
To accomplish this analysis, we explored our clinical outcomes
with anatomic segmentectomy and lobectomy for clinical stage I
NSCLC using a propensity-matched risk model and multivariable
parameter assessment,15,16 because results of randomized studies di-
rectly comparing these anatomic resection approaches are lacking.
PATIENTS AND METHODS
Patients
Approval for this study was provided by the Institutional Review Board
of the University of Pittsburgh, and individual patient consent was waived. We
performed a retrospective analysis of 1,192 patients who underwent anatomic
segmentectomy (n 392) or lobectomy (n 800) for clinical stage I NSCLC
derived from the Lung Cancer Database of the University of Pittsburgh. Pa-
tients were staged according to the seventh edition of the International Union
Against Cancer/American Joint Committee on Cancer lung cancer staging
system. Pathologic information was derived from the published case synoptic
for each patient.
Propensity Score Matching
Propensity score matching is a method for creating similar case (segmen-
tectomy) and control (lobectomy) sets from an existing data set for a retro-
spective analysis.17 The sets are similar in that the cases and controls are
matched on a set of variables that would otherwise confound comparisons
between the cases and controls; in this case, the matching variables would be
those that the surgeon would consider in choosing the type of surgery and
baseline clinical characteristics. The significant potential confounders are
identified by logistic regression, and each patient is assigned a score based on
those confounders. Cases and controls are then matched on those scores,
rather than the individual confounders (which is usually infeasible). The
outcomes (eg, overall survival) can then be compared between the case and
control sets without adjusting for the confounders. Short of a prospective,
randomized trial, this propensity-matching technique provides the fairest
comparison of matched sets in the setting of a retrospective study.
Of the original 1,192 patients in the database, 42 were removed second-
ary to tumor size greater than 5 cm or because their propensity scores could not
be calculated because of missing values, leaving 763 lobectomies and 387
segmentectomies on which the propensity score matching was performed. The
variables for the propensity score matching were chosen by first performing a
logistic regression of segmentectomy versus lobectomy on the following fac-
tors: age (years); sex; ever smoked (yes or no); forced expiratory volume in 1
second (FEV1); preoperative hypertension, chronic obstructive pulmonary
disease (COPD), diabetes mellitus, gastroesophageal reflux disease, coronary
artery disease, or prior cancer history (all yes or no); preoperative estimate of
tumor size (cm); and date of surgery. The potential predictors that were not
statistically significant (P .05) were removed, and the propensity score was
calculated from the logistic regression refit to the reduced variable group,
which included age, FEV1, preoperative COPD, tumor size, and date of sur-
gery. Segmentectomy and lobectomy patients were then matched 1:1 using a
greedy five-digit matching algorithm. Out of the 387 segmentectomy patients
and 763 lobectomy patients, 312 pairs were matched; the 1:1 matching algo-
rithm could not find lobectomies for the remaining 75 segmentectomies.
Patient demographics and tumor characteristics for the matched groups are
listed in Table 1.
Operative Technique
Surgeries performed included 312 lobectomies and 312 anatomic seg-
mentectomies. A video-assisted thoracoscopic surgery approach was used in
54.6% of the patients in this study, with thoracotomy performed in 45.4% of
patients. Anatomic segmentectomy was performed as described previously
using the clinical and anatomic parameters for lesion selection.2,10 Criteria
favoring the use of anatomic segmentectomy include T1 tumors ( 3 cm in
diameter), tumors confined to discrete anatomic segmental boundaries, ab-
sence of proximal segmental bronchial involvement/lesion confined to the
outer half of the lung parenchyma, absence of visceral pleural involvement,
and absence of clinically positive hilar or mediastinal adenopathy.
Anatomic segmentectomy was accomplished by the removal of one or
more pulmonary parenchymal segments with its corresponding bronchovas-
cular and lymphatic supply. In contradistinction to wedge resection (which
does not involve anatomic hilar dissection), anatomic segmentectomy is ac-
complished by individual isolation and division of the targeted segmental
bronchial and vascular structures and complete excision of the segmental
pedicle.18,19 The endostapler was then applied to encompass a parenchymal
margin of resection on the adjacent segment of the lung (extended segmentec-
tomy) ensuring a resection margin equivalent to the diameter of the tu-
mor.10,20 Systematic hilar and mediastinal nodal sampling was then
performed. Lobectomy was also accomplished using the individual isolation,
ligation, and division of the corresponding bronchovascular contributions to
the lobe, similar to the technique used for anatomic segmentectomy. The
distribution of resected segments and lobes is provided in Table 2.
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Segmentectomy
(n  312)
Lobectomy
(n  312)
P
No. of
Patients %
No. of
Patients %
Age, years
Mean 68.5 68.4 .88
SD 9.2 9.2
Sex .75
Male 139 144
Female 173 168
Comorbidities
HTN 165 52.9 152 48.7 .34
DM 57 18.3 44 14.1 .19
COPD 103 33.0 105 33.7 .93
Previous cancer 77 24.7 71 22.8 .64
Smoking status 1.00
Ever 290 92.9 290 92.9
Never 22 7.1 22 7.1
PFTs: FEV1, % .68
Mean 77.8 75.1
SD 22.5 19.7
Histology
Adenocarcinoma 177 56.7 183 58.7 .69
Squamous 89 28.5 97 31.1 .54
Tumor size, cm .88
Mean 2.2 2.2
SD 1.0 1.1
Tumor stage .44
IA 248 239
IB 64 73
Follow-up time, years 5.3 5.4 .86
Abbreviations: COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus; FEV1, forced expiratory volume in 1 second; HTN, hypertension;
PFTs, pulmonary function tests; SD, standard deviation.
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Follow-Up
Perioperative data were actively collected from the hospital chart, anes-
thesia, and operating room records as well as the electronic medical record
and/or office charts for each patient. Complications were documented for each
patient based on standard definitions established for the Society of Thoracic
Surgeons General Thoracic Surgery Database.21 All patients were observed
postoperatively with CT scans at 2 weeks and at 4- to 6-month intervals for the
first 2 years, and then yearly thereafter. Perioperative mortality was defined as
any death within the first 30 days after surgery or during the same hospitaliza-
tion. Ninety-day mortality was also calculated. Locoregional recurrence was
defined as evidence of tumor within the same lobe, the hilum, or the medias-
tinal lymph nodes. Distant recurrences were defined as evidence of tumor in
another lobe, the pleural space, or elsewhere outside the hemithorax. Median
follow-up time was 5.4 years for the entire cohort.
Statistical Analysis
Wilcoxon and t tests were used to compare the distributions of continu-
ous data (age, tumor size, number of lymph nodes removed, operative time,
and estimated blood loss), and the2 or Fisher’s exact test was used to compare
the frequencies of categorical measures (eg, sex, histology, stage) between
lobectomies and segmentectomies. All comparisons were two-tailed. Postop-
erative complications were tabulated and categorized according to those used
in the Society of Thoracic Surgeons National Database.21 Thirty- and 90-day
mortality were also assessed.
Primary outcome variables included freedom from recurrence and over-
all survival. Locoregional recurrence was defined as any recurrence in the
ipsilateral lobe, hilum, or mediastinum for segmentectomy patients and any
hilar or mediastinal recurrence noted for lobectomy patients, without evi-
dence of distant metastases for either resection mode used. Distant recurrence
was defined as any recurrence in a distinctly different lobe of the ipsilateral
lung, contralateral mediastinum, or hilum and extrathoracic metastatic dis-
ease. Freedom from recurrence was defined as the time from surgery to the first
diagnosis of local, regional, or distant disease recurrence or until last follow-up;
death was considered a censoring event for recurrence. Overall survival was
defined as the time from surgery to death or last follow-up. Overall survival
and freedom from recurrence functions were estimated using the Kaplan-
Meier method. Survival functions were compared using the log-rank test.
Multiple clinical variables were evaluated for their association with time
to recurrence in univariable analysis. Variables demonstrating a significant
association with recurrence in univariable analysis (P .05) were then ana-
lyzed in a forward proportional hazards (Cox) regression model. Correspond-
ing hazard ratios, CIs, and P values for each variable were determined using the
SAS software package (SAS Institute, Cary, NC).
RESULTS
Differences Between Matched and
Unmatched Patients
The average age was 66.9 years in the unmatched patients (n
526) and 68.4 years in the matched set (n 624). Mean FEV1 values
were 81.9% and 76.4%, respectively. Average tumor sizes were 2.6 cm
in the unmatched set and 2.2 cm in the matched set. In the unmatched
set, 19.3% of patients had preoperative COPD versus 33.4% of pa-
tients in the matched set. Patients in the matched set had surgery an
average of 4.9 months later (in calendar time) than in the un-
matched set.
Clinical Characteristics
Patient age, sex, comorbidities, pathologic cell type distribution,
and tumor size were equivalent between the matched groups (Table
1). The mean patient age was 68.5 years. The female-to-male ratio was
283:341 for the entire cohort. The vast majority of patients were
current or former smokers (92.9%), with a moderate degree of pul-
monary impairment (FEV1, 76.4%). The mean tumor size was 2.2 cm.
The clinical stage distribution was as follows: stage IA, 487 patients
(78.0%); and stage IB, 137 patients (22.0%). The most common lobar
and segmental resections performed were right upper lobectomy (n
126, 40.4%) and left upper division segmentectomy (n 77, 24.7%),
respectively (Table 2). Lobectomy was associated with a significantly
increased number of harvested lymph nodes compared with segmen-
tectomy (median, 12 v six nodes, respectively; P .001). There was no
significant difference in the number of lymph node stations sampled
with lobectomy versus segmentectomy (median, three v three stations,
respectively; P .45), suggesting that the difference in nodal sampling
was related, at least in part, to the extent of parenchyma resected. Final
pathologic stage distribution was as follows: stage IA, 345 patients
(55.3%); stage IB, 202 patients (32.4%); and stage IIA to IIIB, 77
patients (12.3%). Overall agreement between clinical and pathologic
stage was 63.7%. Pathologic upstaging occurred in 32.3% of patients;
4.0% of patients were downstaged.
Perioperative Outcomes
Overall morbidity was similar between the segmentectomy
(36.9%) and lobectomy (32.7%) groups (P .31). The 30-day mor-
tality rate for segmentectomy was 1.2%, compared with 2.5% for
lobectomy (P .38). The 90-day mortality rates were 2.6% for seg-
mentectomy versus 4.8% for lobectomy (P .20; Table 3).
Recurrence and Survival
At a mean follow-up of 5.4 years, comparing segmentectomy
with lobectomy, no differences were noted in either locoregional
(5.5% v 5.1%, respectively; P  1.00) or distant (14.8% v 11.6%,
respectively; P  .29) recurrence rates. Kaplan-Meier estimates of
freedom from recurrence (70% v 71%, respectively; P  .467) and
overall survival (54% v 60%, respectively; P .258) at 5 years similarly
demonstrated no statistically significant difference between groups
Table 2. Distribution of Anatomic Segmentectomy and
Lobectomy Procedures
Anatomic Location
Lobectomy
(n  312)
Segmentectomy
(n  312)
No. of
Patients %
No. of
Patients %
Right upper lobe
Apical segment 24 7.7
Anterior segment 126 40.4 15 4.8
Posterior segment 37 11.9
Apicoposterior segment 11 3.5
Right middle lobe 28 9.0
Medial segment 2 0.6
Lateral segment 8 2.6
Right lower lobe 43 13.8
Superior segment 38 12.2
Basilar segment 32 10.3
Left upper lobe 85 27.2
Upper division segment 77 24.7
Lingula segment 21 6.7
Left lower lobe 30 9.6
Superior segment 25 8.0
Basilar segment 22 7.1
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(Table 3, Fig 1). Importantly, no significant differences were seen in
time to recurrence when comparing patients with T1a tumors ( 2
cm; P .585), T1b tumors (2 to 3 cm; P .395), or T2a tumors (3 to
5 cm; P .432).
Multivariable Analysis
On univariable analysis, none of the patient or operative variables
analyzed demonstrated an association with recurrence (Table 4). Of
importance, anatomic segmentectomy was not found to be a predictor
of recurrence. When examining predictors of overall survival, age,
male sex, preoperative COPD, preoperative coronary artery disease,
and tumor size (all P .05) were all associated with reduced survival
in univariable and multivariable analyses (Tables 4 and 5). Of impor-
tance, anatomic segmentectomy was not found to be an independent
predictor of recurrence (hazard ratio, 1.11; 95% CI, 0.87 to 1.40) or
overall survival (hazard ratio, 1.17; 95% CI, 0.89 to 1.52).
DISCUSSION
How should we approach the peripheral, small, clinically node-
negative NSCLC today? Pneumonectomy was the standard of care for
resectable lung cancer for nearly two decades.22-26 However, by the late
1950s, lobectomy had surpassed it as the preferred mode of resection
for peripheral lung cancers as a result of observed increases in long-
term survival with lobectomy (19% v 12% for pneumonectomy) at 5
years, as well as a reduction in operative morbidity and mortality.27
These generally poor results by today’s standards can be primarily
attributed to the limitations of clinical staging during that period and
to a near totally subjective evaluation of the associated medical condi-
tions (eg, impaired functional lung reserve, cardiac disease) that affect
early postsurgical and long-term survival.
The findings of large-population CT screening programs for
early lung cancer identification,28-40 coupled with these clinical staging
advances, have led to an increased number of clinically suspicious lung
nodules suggestive of early-stage NSCLC in modern practice. The
following question has thus arisen: Is lobectomy needed for the small
peripheral symptomatic lung nodule serendipitously identified by
CT scanning?41,42
Over the years, our group has been influenced by the insights of
breast surgical oncologists considering lesser resections for small
breast cancers43 and has explored the potential merits of parenchymal
preservation for the patient with lung cancer in the setting of clinical
stage I NSCLC.40-42 Despite a growing number of reports suggesting
the utility of a selective application of sublobar resection, and specifi-
cally anatomic segmentectomy, for peripheral stage I NSCLC, resec-
tion of even the smallest peripheral lung cancer is still considered by
many surgeons as a compromised therapy that should be only
Table 3. Perioperative Outcomes: Segmentectomy Versus Lobectomy
Outcome
Segmentectomy
(n  312) Lobectomy (n  312)
PProportion 95% CI Proportion 95% CI
Mortality
30 day 0.012 0.004 to 0.32 0.025 0.011 to 0.050 .38
90 day 0.026 0.011 to 0.050 0.048 0.027 to 0.078 .20
Site of
recurrence
Locoregional 0.057 0.034 to 0.089 0.057 0.034 to 0.089 1.00
Distant 0.153 0.115 to 0.198 0.127 0.093 to 0.169 .42
5-year freedom
from
recurrence† 0.70 0.63 to 0.78 0.71 0.64 to 0.78 .47‡
5-year overall
survival† 0.54 0.47 to 0.61 0.60 0.54 to 0.67 .26‡
Fisher’s exact test.
†Estimates from Kaplan-Meier survival function estimate and 95% CIs.
‡Log-rank test comparing survival functions.
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Fig 1. Kaplan-Meier survival estimates for (A) time to recurrence and (B) overall survival between propensity score–matched patients undergoing segmentectomy
or lobectomy.
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considered for the physiologically impaired patient who is not a
candidate for anatomic lobectomy.1,4,41 This perception has been
primarily established by the findings of the Lung Cancer Study
Group, which represents the only prospective, multicenter, ran-
domized trial comparing lobectomy with sublobar resection per-
formed to date. In this study, a three-fold increase in the rate of
locoregional recurrence was noted in the sublobar resection arm
compared with the lobectomy arm (17.2% v 6.4%, respectively),
which included patients undergoing either wedge resection or
segmentectomy. Interestingly, we and others have previously
found that anatomic segmentectomy may have a reduced risk of
locoregional recurrence compared with nonanatomic wedge resec-
tion and that anatomic segmentectomy more closely approximates
the oncologic results after lobectomy.42 The results of the current
propensity-matched study suggest that anatomic segmentectomy
can achieve perioperative (morbidity and mortality) and oncologic
outcomes (recurrence and survival) that are not statistically signif-
icantly different compared with those achieved by lobectomy for
clinical stage I disease, and thus anatomic segmentectomy should
be considered as a valid alternative to lobectomy in properly se-
lected patients.
In this study, we also identified that a similar hilar and mediasti-
nal lymph node station examination was accomplished by segmentec-
tomy and lobectomy. Although a greater number of nodes removed
during mediastinal evaluation may lead to greater discovery of sur-
prise node-positive disease, this occurred less than 4% of the time in
the recently reported results of the American College of Surgeons
Oncology Group Z0030 investigation of mediastinal node dissection
versus systematic sampling after resection of stage I NSCLC. Addition-
ally, no improvement in survival could be demonstrated in this trial
with the standard use of mediastinal and hilar node dissection over
systemic sampling.44 In the current study, although lobectomy yielded
a greater absolute number of lymph nodes (median, 12 nodes with
lobectomy v six nodes with segmentectomy; P .001), when compar-
ing segmentectomy with lobectomy, there was no significant differ-
ence in the number of lymph node stations assessed (median of three
lymph node stations in both groups; P .45) or degree of clinical to
pathologic upstaging (36.5% v 29.5%, respectively; P .073), and no
corresponding statistically significant difference in recurrence or over-
all survival (Table 3, Fig 1).
Approaching the problem of small peripheral lung cancer from a
different direction, we see the emergence of enthusiasm with nonsur-
gical image-guided ablative and focused radiotherapeutic approaches
to the small peripheral lung nodule suspicious for lung cancer.11,12,45
The commentary of advocates of nonsurgical approaches to periphe-
ral lung cancer relate to the avoidance of any morbidity related to
surgery with the theoretical possibility of equivalent long-term sur-
vival. But as the saying goes, “pay me now or pay me later.” It seems
that the risk of local lung injury leading to intermediate and late-term
unintended negative consequences, such as progressive radiation
pneumonitis, fibrosis, and loss of pulmonary function,46-48 and the
incremental loss of opportunity to identify a significant minority of
patients with more advanced cancers who may benefit from adjuvant
therapy are concerns.
Today more than ever, we should not be satisfied with the con-
cept of the simple local extirpation of the point of disease presentation
manifested in the apparently locally confined NSCLC. Again, an em-
phasis on improving the overall outcome of clinical stage I NSCLC,
Table 5. Multivariable Analysis of Overall Survival
Factor Hazard Ratio P
Age 1.04  .001
Sex 1.53  .001
Preoperative COPD 1.35 .018
Preoperative CAD 1.83 .003
Tumor size 1.19 .006
Surgery 1.23 .126
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease.
Table 4. Univariable Analysis of Recurrence and Overall Survival
Factor P
Recurrence
Patient variable
Age .849
Sex .111
Ever-smoker .950
Comorbidities
COPD .609
Hypertension .729
Diabetes mellitus .734
CAD .082
GERD .159
Previous cancer history .165
Pulmonary function (FEV1) .606
Operative variables
Surgery .391
Laterality .584
Lobe involved .067
Operative time .818
Lymph nodes examined .140
Tumor size .491
Tumor histology .881
Overall survival
Patient variables
Age  .001
Sex  .001
Ever-smoker .717
Comorbidities
COPD .022
Hypertension .729
Diabetes mellitus .273
CAD .004
GERD .106
Previous cancer history .165
Pulmonary function (FEV1) .089
Operative variables
Surgery .154
Laterality .986
Lobe involved .706
Operative time .143
Tumor size .008
Tumor histology .523
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 second; GERD,
gastroesophageal reflux disease.
Statistically significant.
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which includes patients with occult/surprise lymph node positivity
(identified in up to 30% of patients), mandates the pathologic assess-
ment of the disease through surgical resection. Accordingly, tissue still
remains the issue in the surgical management of early-stage NSCLC,
particularly in this age of individualized therapy for the patient with
lung cancer.49-53 Surgical resection of peripheral lung cancers repre-
sents the standard of care. Similar to the arguments with breast cancer
surgery, the advantages of surgery are pathologic assessment of surgi-
cal margins, the establishment of pathologic regional nodal status,
and, in this era of increasing enthusiasm for adjuvant systemic ther-
apy, provision of tissue for pharmacogenomic assessment.
Limitations of this study include the potential introduction of
surgical and selection bias associated with the retrospective assessment
of prospectively collected data. We have attempted to directly address
this fundamental limitation with the use of propensity matching and
multivariable analysis. Another limitation of this study is that the
presented data are derived from a single institution with expertise in
minimally invasive and open lobectomy and segmentectomy tech-
niques. The generalization of the observed outcomes to broad clinical
practice must therefore be cautiously scrutinized. Multicenter, pro-
spective, randomized studies currently under way (Cancer and Leu-
kemia Group B 140503; Japan Clinical Oncology Group 0802/West
Japan Oncology Group 4607L) will thus be necessary to confirm the
results of this study.
In conclusion, the information obtained from this propensity-
matched analysis supports this concept of anatomic segmental resec-
tion for the small peripheral lung cancer anatomically confined to
segmental boundaries. However, confirmation of clear, generous
margins of resection and the assurance of accurate intraoperative
pathologic nodal staging of the lesion are important considerations
that should lead us to favor lobectomy over segmentectomy when an
issue. For the small peripheral lung cancer, however, anatomic seg-
mentectomy appears to offer comparable local control and the oppor-
tunity for prolonged disease-free and overall survival that is not
statistically different when compared with lobectomy.
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